NASDAQ:PFNX - Pfenex Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$12.75
+0.30 (1.20%)
Get New Pfenex Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PFNX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PFNX

Average Price Target: $0.00
▼ -100.00% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Pfenex in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $12.75.

Hold

The current consensus among 2 contributing investment analysts is to hold stock in Pfenex.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/29/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/17/2020Cantor FitzgeraldDowngradeOverweight ➝ NeutralLow
8/14/2020William BlairDowngradeOutperform ➝ Market PerformLow
10/28/2019Cantor FitzgeraldReiterated RatingOverweightLow
(Data available from 6/21/2016 forward)

Pfenex

Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. The company also develops PF582, a biosimilar candidate to Lucentis; PF529, a biosimilar to Neulasta; and hematology/oncology products, including PF743, a recombinant crisantaspase, as well as PF745, a recombinant crisantaspase with half-life extension technology. In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California.
Read More

Today's Range

Now: $12.75
Low: $12.75
High: $12.75

50 Day Range

MA: $12.74
Low: $12.68
High: $12.86

52 Week Range

Now: $12.75
Low: $5.26
High: $14.00

Volume

N/A

Average Volume

503,865 shs

Market Capitalization

$437.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Pfenex?

The following sell-side analysts have issued stock ratings on Pfenex in the last year: Cantor Fitzgerald, and William Blair.
View the latest analyst ratings for PFNX.

What is the current price target for Pfenex?

0 Wall Street analysts have set twelve-month price targets for Pfenex in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Pfenex in the next year.
View the latest price targets for PFNX.

What is the current consensus analyst rating for Pfenex?

Pfenex currently has 2 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in PFNX, but not buy more shares or sell existing shares.
View the latest ratings for PFNX.

What other companies compete with Pfenex?

How do I contact Pfenex's investor relations team?

The company's listed phone number is 858-352-4400. The official website for Pfenex is www.pfenex.com.